PCV80 TISSUE ENGINEERING OF VALVEDVENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS A PRE-MARKETINGTECHNOLOGY ASSESSMENT APPROACH WITH GERMAN DATA  by Dintsios, CM et al.
angina, stroke, post-stroke, heart failure and death. It has an
annual cycle and estimates mean quality-adjusted survival and
treatment cost, which reﬂects hypertension treatment and the
management of cardiovascular events. Risk functions were used
to conduct extrapolations. Data on treatment effectiveness,
quality-of-life and epidemiology were obtained from published
clinical trials and studies. The database of the main insurance
fund (IKA) was analysed to estimate the cost of events. The
analysis was done from a payer perspective, all outcomes were
discounted at 3% and prices correspond to 2008. RESULTS: The
estimated patient cost per annum for each health state was: stable
angina: €2252; unstable angina: €2572; myocardial infarction:
€2473; post-MI: €1677; stroke: €12,233; post-stroke: €1240;
heart failure: €2655; angiogram: €1544; angioplasty: €6511;
bypass surgery; €11,514. For the baseline group (age: 57 years,
systolic-blood-pressure: 147, cholesterol: 6.00 mmol/L, BMI:
29 kg/m2) with mild/moderate disease, the total cost was €15,146
with irbesartan, €15,486 with losartan and €15,613 valsartan;
QALYs were 12.67, 12.63 and 12.64, respectively. For the group
with severe disease, the total cost with irbesartan) was €15,798
(150 mg) and €18,697 (300 mg), whilst with Losartan was
€16,295 (50 mg) and €22,496 (100 mg); QALYs were 12.47 and
12.37 for irbesartan and losartan respectively. Thus, irbesartan
was less costly and more effective and dominated the other two
treatments. Similar results were obtained in relation to various
other patient groups and several sensitivity analyses. CONCLU-
SIONS: For different patient populations, irbesartan represents
good value for money in the Greek NHS setting, compared to
selected commonly used alternatives.
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OBJECTIVES: The development of a decision model for the
assessment of the emerging technology implantation of valved
venous conduits (VVC) using tissue engineering in patients with
chronic venous insufﬁciency (CVI) versus Conservative treatment
options like horse chestnut seed extract and compression therapy.
METHODS: The model allows to enter parameters for the efﬁ-
cacy, safety, long-term effectiveness, quality of life, disease-speciﬁc
mortality, and costs and to derive (quality-adjusted) life expect-
ancy and cost-effectiveness from a health care system perspective.
It evaluates a lifelong time horizon using the Gompertz function
and applies an annual discount rate of 3%. Cost and epidemio-
logical data of CVI were gathered from literature. The costs for
VVCwere estimated considering the development costs. Finally to
calculate QALYs we surveyed a panel of angiologists and angio-
surgeons presenting the results of animal studies concerning the
functionality, tolerability and hemorheology. RESULTS: A mar-
ginal difference of 0.04 LY in favor of VVC was calculated
incorporating the lethality of the implantation. VVC yielded
additional QALY gains of 2.02 compared to conservative therapy.
Patient implanted with VVC were estimated to reach a utility of
0.64 comparedwith 0.50 for those receiving conservative therapy.
VVC was in the conservative scenario with implantation of up to
four conduits €4395 more expensive; in the scenario with up to
two implanted conduits the difference was only €330. VVC seems
to be cost-effective for CVI patients, with an incremental cost-
effectiveness ratio compared with conservative therapy of 163 to
€2176/QALY. CONCLUSIONS: Especially in the ﬁeld of emerg-
ing technologies, where data from clinical trials are lacking,
decision-analytic modeling even in a pre-market condition is a
useful tool to systematically assess the expected value of technolo-
gies and the related uncertainty. Thereby, developers can avoid
misdirected investment in health care systems ruled by thresholds
even before the diffusion of a technology.
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OBJECTIVES: To model the impact of the addition of ﬁxed-dose
niacin extended-release and simvastatin (NER/S) therapy to a
health plan formulary in terms of optimal low density lipoprotein
cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-
C), and triglyceride (TG) value attainment. METHODS: Two
hypothetical formularies with all major branded and generic lipid
drugs were modeled over a three year time horizon: a formulary
not including NER/S (current formulary) and a formulary which
did (revised formulary). Primary and secondary risk patients with
1 sub-optimal lipid parameter were sampled from the Health-
Core Integrated Research Database between 1/1/2000 and 2/28/
2005. Package insert efﬁcacy of antihyperlipidemic medications
in each formulary was applied to the sample population. Post-
treatment lipid values were evaluated according to U.S. lipid
guidelines. Rates of individual and combined optimal lipid value
(OLV) [LDL-C, HDL-C, and TG] achievement were estimated in
direct proportion to lipid therapy market shares in both formu-
laries. Changes in clinical outcomes between formularies were
evaluated relative to incremental change in pharmacy and car-
diovascular (CV) disease related medical costs. Market penetra-
tion of NER/S was assumed to be 1.5% and payer discounts of
17% and 50% were applied to branded and generic wholesale
acquisition costs. RESULTS: The rate of combined OLV attain-
ment over three years in the revised formulary increased 0.57%
from the current formulary. Attainment of optimal LDL-C,
HDL-C and TG values increased by 0.07%, 0.30%, and 0.10%,
respectively. The cost for a 1% increase in optimal LDL-C,
HDL-C, and TG attainment was $3103, $952, and $2047
respectively. There was an estimated $1147 cost for every 1%
increase in combined OLV attainment. CONCLUSIONS: The
addition of NER/S to the health plan formulary increases indi-
vidual and combined OLV achievement thereby having the
potential to reduce the incidence of CV events and CV-related
medical costs.
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OBJECTIVES: To evaluate changes in low-density lipoprotein
cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-
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